Technical Analysis for ABOS - Acumen Pharmaceuticals, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Fell Below 50 DMA | Bearish | 0.00% | |
| Upper Bollinger Band Walk | Strength | 0.00% | |
| 50 DMA Support | Bullish | -2.14% | |
| MACD Bullish Centerline Cross | Bullish | -2.14% | |
| NR7 | Range Contraction | -2.14% | |
| Stochastic Reached Overbought | Strength | -2.14% | |
| Upper Bollinger Band Walk | Strength | -2.14% | |
| Weak + Overbought | Other | -2.14% | |
| Inside Day | Range Contraction | -2.14% | |
| Weak, Overbought and Reversal Signs | Reversal | -2.14% |
| Alert | Time |
|---|---|
| Fell Below 50 DMA | 1 day ago |
| 50 DMA Support | 1 day ago |
| Down 3% | 1 day ago |
| Fell Below Previous Day's Low | 1 day ago |
| Down 2 % | 1 day ago |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/14/2024
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapeutics for the treatment of Alzheimer's and other neurodegenerative diseases. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, which is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is based in Charlottesville, Virginia.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Biology Immunotherapy Alzheimer's Disease Neurodegenerative Diseases Amyloid Amyloidosis Neurodegeneration Regulus Therapeutics Targeted Immunotherapy Treatment Of Alzheimer's Amyloid Beta
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Biology Immunotherapy Alzheimer's Disease Neurodegenerative Diseases Amyloid Amyloidosis Neurodegeneration Regulus Therapeutics Targeted Immunotherapy Treatment Of Alzheimer's Amyloid Beta
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 11.3099 |
| 52 Week Low | 1.8101 |
| Average Volume | 265,113 |
| 200-Day Moving Average | 3.91 |
| 50-Day Moving Average | 3.71 |
| 20-Day Moving Average | 3.40 |
| 10-Day Moving Average | 3.55 |
| Average True Range | 0.23 |
| RSI (14) | 54.13 |
| ADX | 20.11 |
| +DI | 23.67 |
| -DI | 19.03 |
| Chandelier Exit (Long, 3 ATRs) | 3.24 |
| Chandelier Exit (Short, 3 ATRs) | 3.75 |
| Upper Bollinger Bands | 3.81 |
| Lower Bollinger Band | 2.98 |
| Percent B (%b) | 0.8 |
| BandWidth | 24.54 |
| MACD Line | 0.02 |
| MACD Signal Line | -0.04 |
| MACD Histogram | 0.0621 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 3.96 | ||||
| Resistance 3 (R3) | 3.96 | 3.87 | 3.91 | ||
| Resistance 2 (R2) | 3.87 | 3.79 | 3.86 | 3.89 | |
| Resistance 1 (R1) | 3.76 | 3.74 | 3.71 | 3.75 | 3.87 |
| Pivot Point | 3.66 | 3.66 | 3.63 | 3.66 | 3.66 |
| Support 1 (S1) | 3.55 | 3.58 | 3.50 | 3.55 | 3.43 |
| Support 2 (S2) | 3.45 | 3.53 | 3.45 | 3.41 | |
| Support 3 (S3) | 3.34 | 3.45 | 3.39 | ||
| Support 4 (S4) | 3.34 |
